Malignant Neoplasms
|
0.400 |
GenomicAlterations
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
<b>Objectives:</b> Two functional polymorphisms in the <i>MDM2</i> promoter region, SNP309T>G and SNP285G>C, have been shown to impact MDM2 expression and cancer risk.
|
28819417 |
2017 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
|
17116689 |
2007 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mdm2 amplification in benign tumors suggests that it is not sufficient for p53 inactivation in cancer, implying that other defects in the p53 pathway are required for malignancy.
|
14555661 |
2003 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 may also be associated with drug resistance in cancer chemotherapy.
|
15720187 |
2005 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 staining was noted in the nucleus of cancer and non-cancer cells.
|
16308103 |
2005 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Hdm2 synthesis is itself tightly controlled and, as demonstrated by a recently described SNP (SNP309) in the hdm2-P2 promoter, minor variations in Hdm2 expression have phenotypic consequences on radiation sensitivity and cancer predisposition.
|
16501602 |
2006 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 SNP309 and cancer risk: a combined analysis.
|
17827408 |
2007 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Mdm2, a regulator of the tumor suppressor p53, is frequently overexpressed in human malignancies.
|
18541670 |
2008 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.
|
21436469 |
2011 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Mdm2, a key regulator of the p53 tumor suppressor and modulator of DNA break repair, is frequently overexpressed in malignancies and contributes to CIN.
|
21602883 |
2011 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MDM2 is overexpressed and amplified in a number of malignant tumors including breast carcinomas.
|
21896991 |
2011 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 SNP309 has potential as a biomarker of cervical neoplasia in non-smokers, patients with family history of cancer, or those who had late sexual debut (>16 years).
|
25271042 |
2014 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2/4 antagonists, on the other hand, are likely to be efficacious in malignancies in which MDM2 or MDM4 is overexpressed such as sarcomas, neuroblastomas and specific childhood leukemias.
|
25455730 |
2014 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MDM2 overexpression in various cancer cell lines causes p14ARF reduction inducing its degradation through the proteasome.
|
25723571 |
2015 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MDM2-309T>G a functional promoter polymorphism was found to be associated with overexpression thereby attenuation of Tp53 stress response and increased cancer susceptibility.
|
25854351 |
2015 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 gene amplification (n = 9) and chromosomal aberrations (trisomy, n = 47; high polysomy, n = 7) are linked to high-grade malignancy (P < 0.001), lymph node metastasis (P = 0.001), advanced tumour size (P = 0.013) and stage (P < 0.001), gender (P = 0.002) and age (P = 0.001).
|
26661925 |
2016 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mdm2 and Mdmx are critical regulators of the p53 tumour suppressor and are overexpressed in many human malignancies.
|
27932484 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 immunohistochemical staining was also negative, leading to the diagnosis of Fédération Nationale des Centres de Lutte contre le Cancer grade III undifferentiated pleomorphic sarcoma (UPS).
|
28105789 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mdm2 transcripts undergo alternative splicing, and Mdm2 splice isoforms are increased in cancer and induced by DNA damage.
|
28166445 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 is known to be amplified in numerous human cancers, and upregulation of MDM2 is considered to be an alternative mechanism of p53 inactivation.
|
28415963 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells.
|
28576884 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 regulates cancer cell proliferation, cell cycle progression, apoptosis, migration, and invasion through both p53-dependent and -independent mechanisms.
|
29096894 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 is an oncogene implicated in cancer development.
|
30271790 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2-mediated PER2 turnover was important for defining the circadian period length in mammalian cells, a finding that emphasizes the connection between the circadian clock and cancer.
|
30425162 |
2018 |